ProMIS Neurosciences, Inc. (PMN)

1,7900 -0,1300 (-6,77%) Alla chiusura: 04:00PM EDT

ProMIS Neurosciences, Inc.

1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada
416 847 6898
https://www.promisneurosciences.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 6

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Eugene Williams	Co-Founder & Chairman	275k	N/D	1959
Mr. Neil K. Warma M.B.A.	President, Interim CEO, Principal Executive Officer & Director	40k	N/D	1963
Dr. Neil R. Cashman M.D.	Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director	359,66k	N/D	1952
Mr. Gavin T. Malenfant	Chief Operating Officer	416,73k	N/D	1964
Mr. Daniel E. Geffken M.B.A.	Chief Financial Officer	89,07k	N/D	1957
Dr. Johanne Kaplan Ph.D.	Chief Development Officer	260,4k	N/D	1960
Dr. Ernest D. Bush Ph.D.	Head of Pharmacology/Toxicology & Senior Consultant	N/D	N/D	N/D
Dr. David Wishart Ph.D.	Chief Physics Officer	N/D	N/D	N/D
Mr. Dennis Chen Ph.D.	Head of Manufacturing & Senior Consultant	N/D	N/D	N/D
Dr. Larry Douglas Altstiel M.D., Ph.D.	Chief Medical Officer	N/D	N/D	1950

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Governance aziendale

L'ISS Governance QualityScore di ProMIS Neurosciences, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.